In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Becton, Dickinson and Company

https://www.bd.com/en-us

Latest From Becton, Dickinson and Company

Dr Reddy's Isolates Data Service Centers Among Preventive Actions Responding To Cyberattack

Following cyberattack, chief information officer Mukesh Rathi said Dr Reddy's was “anticipating all services to be up within 24 hours,” adding that “we do not foresee any major impact on our operations due to this incident.”

Commercial Cybersecurity

One Edwards Lifesciences Site Chopped Its Open CAPAs By Half. Here’s How Your Firm Can Too

Two Edwards quality experts explain to Medtech Insight how the firm is benefiting by using a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach that separates higher-risk events from others that don’t need to be elevated to the level of a traditional CAPA.

Quality Control Compliance

Digital Acceleration: Low-Hanging Fruit And Stretch Goals

COVID-19 has pushed the entire health care system to adopt new technologies and new solutions for conducting clinical research and delivering care to patients. An expert panel hosted by the Galien Foundation provided a meditation on what the biopharma industry has learned so far, and how to use the urgency created by COVID-19 to lock-in technological acceleration while maintaining what FDA’s Amy Abernethy called  “responsible progress.”

Coronavirus COVID-19 Digital Health

India Q2 Preview: Glenmark, Cipla Emerge Stronger

With the impact of pandemic-prompted disturbances waning, analysts forecast better Q2 numbers for Indian pharma firms, with some including Glenmark and Cipla seen emerging winners. But after doing well in the quarter, Gilead’s licensees might see remdesivir demand tapering somewhat in Q3 post the WHO finding the antiviral ineffective in COVID-19 treatment.

Commercial Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • BD
    • BD Medical
    • Bridger Biomed, Inc.
    • Caesarea Medical Electronics
    • CareFusion
    • Carmel Pharma, Inc.
    • Carmel Pharma, AB
    • Cellular Research, Inc.
    • C.R. Bard, Inc.
    • CRISI Medical Systems
    • Davol, Inc.
    • Embo Medical Limited
    • FlowCardia, Inc.
    • GenCell Biosystems, Ltd.
    • GeneOhm Sciences
    • Liberator Medical, Inc.
    • Lutonix, Inc.
    • Medafor, Inc.
    • Medicon, Inc.
    • Neomend, Inc.
    • Sirigen Group Limited
    • TriPath Imaging
    • TVA Medical, Inc.
    • Rochester Medical, Inc.
    • Safety Syringes Inc.
    • Vascular Pathways, Inc.
UsernamePublicRestriction

Register